KB-1436

PF07275315-TSLP-hIgG1

45696

Home » Antibodies » PF07275315-TSLP-hIgG1

Background of PF07275315-TSLP-hIgG1

Distinguished as a tri-specific monoclonal antibody, PF-07275315 exerts its therapeutic effect by targeting three key entities: thymic stromal lymphopoietin (TSLP), interleukin 4 (IL-4), and interleukin 13 (IL-13). By engaging with these specific targets, PF-07275315 aims to modulate the underlying immune pathways implicated in the pathogenesis of atopic dermatitis, thereby offering potential relief for affected individuals.

Specifications

Catalog Number	KB-1436
Antibody Name	PF07275315-TSLP-hIgG1
Isotype	Human IgG1,lambda
Target	TSLP
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis.
PF-07275315 by Pfizer for Atopic Dermatitis (Atopic Eczema): Likelihood of Approval.